Published 8 days ago • loading... • Updated 8 days ago

Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine

On Thursday, Hangzhou Diagens Biotech Co., Ltd. announced its first annual results since listing, reporting revenue of RMB 164 million, a 133.7% year-on-year increase.
Technology licensing revenue surged 331.7% to RMB 84.34 million, driven by the proprietary iMedImage foundation model covering 19 imaging modalities and 26 clinical specialties.
Diagens' reach now extends to over 400 medical institutions across China, including 40% of the nation's top ten hospitals, with 65 top-tier hospitals incubating 92 specialized models.
Chairman Ning Song stated the results reflect "a fundamental shift in how medical services are produced and delivered," emphasizing the company's commitment to accessible clinical-grade AI.
Diagens plans to deepen strategic collaboration with Tencent to build a "Device + Service + Data" hub, positioning the company to strengthen global healthcare infrastructure.

Insights by Ground AI

30 Articles

InsideNoVA.com

+28 Reposted by 28 other sources

Center

Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine

HONG KONG and HANGZHOU, China, April 30, 2026 /PRNewswire/ -- Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, "Diagens"), a pioneer in medical imaging foundation models, today announced its first annual results since its listing. The report marks a pivotal milestone…

8 days ago

Read Full Article